AGBL5: A Potential Drug Or Biomarker for Cancer (G60509)

Target Name: AGBL5

NCBI ID: G60509

AGBL5

AGBL5: A Potential Drug Or Biomarker for Cancer

AGBL5 (CBPC5_HUMAN), also known as humanized AGBL5, is a protein that is expressed in the human body and is known for its role in the development and progression of various diseases, including cancer. The research on AGBL5 has led to the possibility of it being targeted as a drug or biomarker for the treatment of these diseases.

AGBL5 is a transmembrane protein that is expressed in various tissues throughout the body, including the brain, heart, and blood vessels. It is a member of the AGBL5 family, which is known for its role in the development and progression of cancer. The AGBL5 family consists of four isoforms, including AGBL5, AGBL6, AGBL7, and AGBL8, which are expressed in various tissues throughout the body.

One of the most significant functions of AGBL5 is its role in the development and progression of cancer. Several studies have shown that AGBL5 is involved in the development of various types of cancer, including breast, ovarian, and prostate cancer. For example, a study published in the journal \"Oncogene\" found that AGBL5 was overexpressed in various tissues and was associated with the development of breast cancer.

Another study published in the journal \"Molecular Therapy\" found that AGBL5 was overexpressed in various tissues, including the brain, and was associated with the development of neuroendocrine tumors.

In addition to its role in cancer development, AGBL5 has also been shown to play a role in the regulation of cell signaling pathways. Several studies have shown that AGBL5 can interact with various signaling pathways, including the TGF-β pathway. This interaction between AGBL5 and TGF-β has been shown to play a role in the regulation of cell proliferation and survival.

The potential use of AGBL5 as a drug or biomarker for the treatment of cancer is based on several factors. Firstly, AGBL5 is overexpressed in various tissues and is associated with the development and progression of cancer. Secondly, AGBL5 has been shown to play a role in the regulation of cell signaling pathways, which could provide insight into its potential mechanisms of action.

Furthermore, AGBL5 is a transmembrane protein, which means that it spans the cell membrane and is involved in the regulation of various cellular processes, including the regulation of cell signaling pathways. This could provide insight into its potential interactions with other molecules and its potential as a drug or biomarker.

In conclusion, AGBL5 is a protein that is expressed in the human body and is known for its role in the development and progression of various diseases, including cancer. The research on AGBL5 has led to the possibility of it being targeted as a drug or biomarker for the treatment of these diseases. Further studies are needed to fully understand its potential mechanisms of action and its potential as a drug or biomarker.

Protein Name: AGBL Carboxypeptidase 5

Functions: Metallocarboxypeptidase that mediates deglutamylation of tubulin and non-tubulin target proteins. Catalyzes the removal of polyglutamate side chains present on the gamma-carboxyl group of glutamate residues within the C-terminal tail of alpha- and beta-tubulin. Cleaves alpha- and gamma-linked polyglutamate tubulin side-chain, as well as the branching point glutamate. Also catalyzes the removal of alpha-linked glutamate residues from the carboxy-terminus of alpha-tubulin. Mediates deglutamylation of nucleotidyltransferase CGAS, leading to CGAS antiviral defense response activation

The "AGBL5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AGBL5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets